Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dolasetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 7/20 | 0.72 |
| ▸ | HTR3B | O95264 | 7/20 | 0.72 |
| ▸ | HTR3D | Q70Z44 | 7/20 | 0.72 |
| ▸ | HTR3C | Q8WXA8 | 7/20 | 0.72 |
| ▸ | HTR1A | P08908 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.72 |
| ▸ | HTR1D | P28221 | 1/20 | 0.72 |
| ▸ | HTR1B | P28222 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | HTR2C | P28335 | 1/20 | 0.72 |
| ▸ | HTR1E | P28566 | 1/20 | 0.72 |
| ▸ | HTR1F | P30939 | 1/20 | 0.72 |
| ▸ | HTR7 | P34969 | 1/20 | 0.72 |
| ▸ | HTR5A | P47898 | 1/20 | 0.72 |
| ▸ | HTR6 | P50406 | 1/20 | 0.72 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dolasetron SCHEMBL29356821 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL29390207 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL13575734 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL1819898 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL42064 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL24914047 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL1819896 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL14014809 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL20769824 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL4450258 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518034-B2 | Synthesis of chiral enaminones, their derivatives, and bioactivity studies thereof | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518034-B2 | Synthesis of chiral enaminones, their derivatives, and bioactivity studies thereof | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150105552-A1 | SYNTHESIS OF CHIRAL ENAMINONES, THEIR DERIVATIVES, AND BIOACTIVITY STUDIES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-04-16 | — | — | US | disclosed |
| US-20150105552-A1 | SYNTHESIS OF CHIRAL ENAMINONES, THEIR DERIVATIVES, AND BIOACTIVITY STUDIES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-04-16 | — | — | US | disclosed |
| EP-2060557-B1 | Intermediate compounds useful to prepare dolasetron | INKE SA (ES) | 2012-06-06 | — | — | EP | disclosed |
| US-7858821-B2 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2010-12-28 | — | — | US | disclosed |
| US-7858821-B2 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2010-12-28 | — | — | US | disclosed |
| WO-2010111136-A2 | ALISKIREN MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-7745628-B2 | Method for obtaining a pharmaceutically active compound, synthesis intermediates thereof and methods for obtaining them | INKE, S.A. (ES) | 2010-06-29 | — | — | US | disclosed |
| US-7608714-B2 | Production of dolasetron | TEVA Gyógyszergyár Zártkörúen Müködö Részvénytársaság (HU) | 2009-10-27 | — | — | US | disclosed |
| US-20070203176-A1 | Crystalline forms of dolasetron base and processes for preparation thereof | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2007-08-30 | — | — | US | disclosed |
| US-20070203176-A1 | Crystalline forms of dolasetron base and processes for preparation thereof | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2007-08-30 | — | — | US | disclosed |
| US-20070203177-A1 | Forms of dolasetron mesylate and processes for their preparation | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2007-08-30 | — | — | US | disclosed |
| US-20070203177-A1 | Forms of dolasetron mesylate and processes for their preparation | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2007-08-30 | — | — | US | disclosed |
| US-20070203219-A1 | Production of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203219-A1 | Production of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203175-A1 | Productioin of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007081907-A2 | CRYSTALLINE FORMS OF DOLASETRON BASE AND PROCESSES FOR PREPARATION THEREOF | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007081890-A2 | PRODUCTION OF DOLASETRON | TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007003522-A1 | METHOD FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND, SYNTHESIS INTERMEDIATES THEREOF AND METHODS FOR OBTAINING THEM | INKE, S.A. (ES) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203177-A1 | Forms of dolasetron mesylate and processes for their preparation | DDOST, DAD1, TYMP | HTR3A 257/4885KCNH2 1372/4885SLC6A4 307/4885 |
| US-20150105552-A1 | SYNTHESIS OF CHIRAL ENAMINONES, THEIR DERIVATIVES, AND BIOACTIVITY STUDIES THEREOF | CYP51A1, LSS, PRMT7 | HTR3A 3621/4885KCNH2 1489/4885SLC6A4 3539/4885 |
| US-20070203175-A1 | Productioin of dolasetron | DDOST, ALG8, DUT | HTR3A 253/4885KCNH2 1308/4885SLC6A4 2447/4885 |
| US-20070203219-A1 | Production of dolasetron | DDOST, DAD1, DHPS | HTR3A 647/4885KCNH2 1268/4885SLC6A4 512/4885 |
| US-20070203176-A1 | Crystalline forms of dolasetron base and processes for preparation thereof | DAD1, DDOST, ALG8 | HTR3A 871/4885KCNH2 1149/4885SLC6A4 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.